Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression by Munaut, Carine et al.
Published in: Neuropathology & Applied Neurobiology (2002), vol. 28, iss. 6, pp. 452-460. 
Status : Postprint (Author’s version) 
 
Macrophage migration inhibitory factor (MIF) expression in human 
glioblastomas correlates with vascular endothelial growth factor (VEGF) 
expression 
 
C. Munaut*, J. Boniver†, J.-M. Foidart* and M. Deprez†
*Laboratoire de Biologie des Tumeurs et du Développement and †Laboratoire de Neuropathologie, Université de Liège, Belgium 
 
Abstract 
Macrophage migration inhibitory factor (MIF) is a peptide released upon hypothalamo-pituitary stimulation that 
acts as a potent endogenous antagonist of the glucocorticoid inhibition of acute inflammatory response and 
subsequent antigen-specific response. MIF also sustains tumour growth as it promotes angiogenesis, overcomes 
p53-mediated cell growth arrest and inhibits tumour-specific immune responses. Using quantitative reverse 
transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry we studied MIF expression in 35 
human glioblastomas and two normal brains. We compared these results with the expression of vascular 
endothelial growth factor (VEGF), the most potent angiogenic factor in glioblastomas. We detected MIF in 
normal cortical neurons and glial cells. All glioblastomas were positive for MIF mRNA with expression levels 
similar to or higher than those of normal brain. MIF immunoreactivity was seen mainly in tumour cells and less 
frequently in hyperplastic endothelial cells. The expressions of MIF and VEGF mRNA were strongly correlated 
(P < 0.0001). Our results demonstrate the expression of MIF in human glioblastomas, and indicate a close 
relationship with VEGF expression. This is of particular interest given the potential modulation of MIF by 
glucocorticosteroids. 
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Introduction 
Looking at the differential expression of an array of 6000 genes in the normal brain and in four glioblastomas 
(GBMs), Markert et al. [14] reported a specific upregulation of the macrophage migration inhibitory factor 
(MIF) in 3/4 GBMs. It has been hypothesized that MIF sustains tumour growth by multiple mechanisms. MIF 
inhibits p53 suppressor activity in vitro [9], which could be relevant in astrocytic gliomas where the loss of p53 
tumour suppressor activity is a common finding [11]. MIF also shows angiogenic activity both in vitro [22] and 
in vivo [6]. Interestingly, GBMs display a prominent angiogenesis and endothelial hyperplasia. In addition, MIF 
acts as the most potent endogenous antagonist of glucocorticosteroid at both a local and a systemic level (for a 
review, see Metz et al. [16]), while MIF secretion and production are both modulated by exogenous 
corticosteroids. These properties might affect the response of GBMs to glucocorticosteroid therapy, currently 
used in the management of GBMs. 
We therefore studied the expression of MIF in a series of 35 human GBMs and in two normal brains using 
immunohistochemistry in all cases and reverse transcriptase polymerase chain reaction (RT-PCR) in 22 cases for 
which frozen tissue was available. 
We further compared MIF expression with the expression of the isoforms of the vascular endothelial growth 
factor (VEGF), known for its angiogenic role in GBMs [13]. 
Materials and methods 
Patient selection 
We investigated 35 histologically proven GBMs examined at the Laboratory of Neuropathology CHU Liège, 
between 1997 and 2001. The series included 29 primary GBMs (i.e. no previous history of lower grade diffuse 
astrocytoma) and six secondary GBMs (i.e. previous history of lower grade diffuse astrocytoma). The sex ratio 
was 18F/17M, and the age at time of diagnosis ranged from 32 to 79 years with a mean value of 53 years. At 
time of surgery all patients were given solumedrol 125 mg intravenously. There was no recent prior history of 
corticotherapy. Immunostaining for p53 was performed in 32 cases: positive staining, defined as the presence of 
at least 10% positive nuclei in 10 consecutive high power (400×) tumour fields, was present in 17/32. Normal 
brain cortex and white matter were obtained from two specimens of temporal lobes resected for intractable 
epilepsy. This study was approved by the Ethical Committee of the Faculty of Medicine of the University of 
Liège. 
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RNA extraction and cDNA synthesis 
Total RNA was extracted from cryosections with the RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany) 
according to the manufacturer's protocol. One microgram of total RNA was reverse transcribed with a 
ThermoScript reverse transcriptase (ThermoScript™ RT-PCR System, Invitrogen, Carlsbad, CA, USA) and 
random hexamer as primer. 
Primers 
Primers (Table 1) for the VEGF gene (GenBank accession no. AH001553) were chosen to distinguish VEGF189, 
VEGF165, VEGF145 and VEGF121 mRNA isoforms. Primers for the human MIF-1 gene (GenBank accession no. 
NM_002415) were chosen using the primer design software Primer Express™ (Perkin-Elmer Applied 
Biosystems, Branchburg, New Jersey, USA). We conducted BLASTn (National Center for Biotechnology 
Information, Bethesda, MA, USA) searches against dbEST and the nonredundant set of GenBank, EMBL, and 
DDBJ database sequences to confirm the total gene specificity of the nucleotide sequences chosen for the 
primers. The 18S ribosomal RNA was measured using the Pre-Developed TaqMan Assay Reagents Endogenous 
control kit from Applied Biosystems. 
 
Table 1    Primers used in PCR analysis 
Gene Accession no. Primers Position 
MIF-1 NM_002415 5'-GAACCGCTCCTACAGCAAGCT-3' (forward primer) 313-441 
  5'-GCGAAGGTGGAGTTGTTCCA-3' (reverse primer)  
VEGF AH001553 5'-CCTGGTGGACATCTTCCAGGAGTA-3' (forward primer) 1208-1687 
  5'-CTCACCGCCTCGGCTTGTCACA-3' (reverse primer)  
 
Quantitative end-point PCR for VEGF mRNA isoforms 
VEGF189, VEGF165, VEGF145 and VEGF121 mRNA isoforms were measured in 10 ng aliquots of cDNA using 
Taq polymerase (Takara, Shigu, Japan) and 5 pmol of each primer (Table 1). The thermal cycling conditions 
included 2 min at 95°C for denaturation and then amplification for 15 s at 94°C, 20s at 66°C and 30 s at 72°C 
(33 cycles for VEGF isoforms) with a final incubation of 2 min at 72°C. PCR products were resolved on 2% 
Nusieve 3:1 agarose gels (BioWhittaker, Rockland, USA) and analysed using a Fluor-S Multilmager (Bio-Rad, 
Hercule, CA, USA) after ethidium bromide staining. The expected sizes for VEGF189, VEGF165, VEGF145 and 
VEGF120 were, respectively, 479, 407, 347 and 275 bp. VEGF mRNA levels were expressed as the ratio of 
VEGF transcripts to 18S transcripts. The experiments were repeated at least three times in duplicate. 
Real-time quantitative PCR 
The quantification of the starting amount of the MIF mRNA in an unknown sample was performed by preparing 
a standard curve using known dilutions of a cDNA. PCR amplification was performed using the SYBR Green 
PCR master mix for MIF mRNA or the TaqMan universal PCR master mix and the Pre-Developed TaqMan 
Assay Reagents Endogenous Control kit for 18S rRNA (PE Applied Biosystems) according to the manufacturer's 
protocol. The thermal cycling conditions included 2 min at 50°C, 10 min at 95°C and then 40 cycles of 
amplification for 15 s at 95°C and 1 min at 60°C. The ABI PRISM 7700 Sequence Detection System instrument 
(PE Applied Biosystems) was used to measure fluorescence in real time. To confirm amplification specificity, 
the PCR products were also examined by subsequent 2% agarose gel electrophoresis. 
For each experimental sample, the amounts of the MIF and 18S rRNA were determined from the calibration 
curve. The target amount was then divided by 18S rRNA to obtain a normalized target value (as described by the 
manufacturer PE Applied Biosystems in User Bulletin no. 2). The experiments were repeated at least three times 
in duplicate. 
Immunohistochemistry for MIF and VEGF 
Sections (thickness 4 µm) were cut from formalin-fixed, paraffin-embedded tumour tissue. They were hydrated 
through graded alcohols, incubated in H2O2 (0.3%, 15 min) and blocked in normal rabbit serum (1:10, 1 h, 
Vector, Burlingame, CA, USA). Sections were autoclaved for 11 min at 126°C in citrate buffer pH 6 for antigen 
retrieval. They were incubated in primary polyclonal antibody (Ab) anti-MIF 1:250 (R&D, Minneapolis, MN, 
USA) or anti-VEGF 1:150 (Santa Cruz, Santa Cruz, CA, USA) for 1 h at room temperature, followed by 
secondary Ab (1 h) and avidin-linked horseradish peroxidase (30 min, Dako, Glostrup, Denmark). 
Immunoreactivity was visualized with 3,3'-diaminobenzidine (DAB+, Dako). Negative controls were obtained 
by omitting the primary antibody. Samples of human anterior pituitary obtained from post-mortem cases were 
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used as positive controls for MIF: they showed a characteristic mosaic pattern due to selective staining of 
corticotrophin (ACTH)- and thyrotrophin (TSH)-producing cells in accordance with previous reports (Figure 1a) 
[17,23]. In tumour specimens, the immunopositivity was assessed semiquantitatively, based on the density of 
positive cells with 0 = complete absence, 1 = rare strongly positive cells, 2 = moderate density of positive cells, 
and 3 = strong diffuse positivity. 
Statistics 
Given the relatively small sample size, we chose nonparametric tests for correlation studies. We used Spearman's 
test to look for correlation between MIF mRNA, VEGF mRNA and age of the patients. Samples were further 
grouped according to results of MIF, VEGF and p53 immunohistochemistry and tumour subtypes. Correlation 
between groups was assessed using Mann-Whitney and Kruskal-Wallis tests. Two-tailed P-values were 
considered significant at <0.05. Statistical analyses were performed using prism 3.0 software (GraphPad, San 
Diego, CA, USA). 
Results 
Expression of MIF 
RT-PCR showed a basal expression of MIF mRNA in both of the samples of normal brain (Figure 2). By 
immunohistochemistry, MIF was detected in the cortex in some pyramidal neurons and in a few glial cells, 
showing strong cytoplasmic positivity. A weaker diffuse staining was also seen in the cortical neuropile (Figure 
1b). 
MIF expression was seen in all GBMs, with variable intensity: in 5/20 cases mRNA expression was at least 
twice as high as in the normal brain; the other tumours showed mRNA levels in the range of normal brain values. 
Immunostaining for MIF was mainly seen in tumour cells with a frequent additional staining of hyperplastic 
endothelial cells in proliferating capillaries (Figure 1c). We found no correlation between the scores of MIF 
immunostaining (Table 2) and the level of mRNA expression in the tumours (P = 0.3841, Kruskal-Wallis test). 
Interestingly, a strong immunopositivity for MIF was also detected in reactive astrocytes scattered in the 
surrounding peritumoral oedema (Figure 1d). No correlation was found between the levels of MIF mRNA and 
the subtype of glioblastoma (P = 0.1689, Mann-Whitney test), the age of patients (P = 0.6451, Spearman test) 
and p53 immunostaining status (P = 0.1388, Mann-Whitney test). 
Expression of VEGF 
Expression of VEGF mRNA was minimal in normal brain (Figure 3). By immunohistochemistry, VEGF peptide 
was localized to the endothelium of rare capillaries in the white matter (Figure 1f). In GBMs, the expression of 
VEGF mRNA was highly variable, ranging from values similar to normal brain to a 15-fold increase (Figure 
3a,b): 14/20 (70%) cases showed mRNA levels at least two times those of normal brain values. By 
immunohistochemistry 29/35 (83%) cases showed a positive staining of hyperplastic endothelium and/or tumour 
cells (Figure le). The immunostaining was generally stronger on endothelial cells than on tumour cells. When 
present in specimens, VEGF positivity was diffuse and there was no spatial restriction to perinecrotic areas. 
There was no labelling of peritumoral reactive astrocytes. We found no correlation between the intensity of 
VEGF immunopositivity (Table 2) and the level of VEGF mRNA (P = 0.5478, Kruskal-Wallis test), age of 
patients (P = 0.2995, Spearman test), tumour subtype (P = 0.3971, Mann-Whitney test), and p53 immunostatus 
(P = 0.1672, Mann-Whitney test). 
The expression pattern of VEGF mRNA isoforms was similar in normal brain and GBMs, with a predominant 
representation of the VEGF165 and VEGF121 isoforms (Figure 3 c). 
Correlation between MIF and VEGF 
Using quantitative RT-PCR, we showed a strong correlation (P< 0.0001, Spearman test) between the expression 
of MIF and VEGF mRNAs (Figure 4). Interestingly, the scores for MIF and VEGF immunostaining correlated 
significantly (P = 0.0329, Kruskal-Wallis test). Although no double immunostaining was performed for MIF and 
VEGF, examination of serial sections suggested in several cases a strong coexpression of MIF and VEGF by 
tumour cells. We found no correlation between MIF immunohistochemistry and VEGF mRNA levels (P = 






Published in: Neuropathology & Applied Neurobiology (2002), vol. 28, iss. 6, pp. 452-460. 
Status : Postprint (Author’s version) 
 
Figure 1. (a-d) MIF immunostaining, Original magnification × 400. (a) Mosaic staining in normal human 
anterior pituitary. (b) Normal brain cortex showing positive staining in the perikaryon of some pyramidal 
neurons (arrows) and in possible glial cells (open arrow). (c) Glioblastoma: a strong staining is seen in the 
cytoplasm of tumour cells and hyperplastic endothelium (arrow). (d) Staining of reactive astrocytes in the 
peritumoral oedema. (e,f) VEGF immunostaining, Original magnification × 400. The strong positivity of tumour 
cells and hyperplastic endothelium (arrow) in GBM (e) contrasts with the staining of flat endothelial cells in 
rare capillaries of normal white matter (f). 
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Figure 2. MIF mRNA quantification. (a) Representative 2% agarose gel of MIF mRNA in normal brain and 
GBM samples. (b) Real-time quantification for normal brain (N, n = 2) and GBMs (GB, n = 20). Values are 

















































MIF 1 1 3 3 2 2 3 2 3 3 1 1 3 2 1 1 2 2 2 3 1 2 
VEGF 0 1 2 2 2 1 0 2 2 2 1 2 3 2 1 1 0 2 2 3 0 2 
N, normal brain; GB, glioblastoma. Scores for immunopositivity were read as follow: 0 = complete absence of positive cells, 1 = rare 
strongly positive cells, 2 = moderate density of positive cells, and 3 = strong diffuse positivity 
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Figure 3. VEGF mRNA quantification. (a) Representative 2% agarose gels of RT-PCR products. VEGF mRNA 
isoforms 189, 165, 145 and 121 are detected, respectively, at 479, 407, 347 and 275 bp. (b) Quantification of 
total VEGF mRNA. (c) Quantification of the isoforms of VEGF mRNA. Proportional representation (%) of each 
isoform. Values are means ± SD in each tissue sample. Experiment repeated at least three times in duplicate. 
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In this study, we used RT-PCR and immunohistochemistry to assess the expression of MIF and VEGF in the 
normal human brain and in a series of 35 GBMs. We further looked for a correlation between MIF and VEGF 
expression. Our specimens of normal brain showed a constitutive expression of MIF. The peptide was detected 
mainly in neurons and in a few glial cells. MIF has been demonstrated previously in the brain of rodents in 
normal conditions and localized to some neurons of the cortex, hypothalamus, hippocampus, cerebellum and 
pons, and to a smaller component of glial cells [3,16,20,24]. MIF function in the normal brain is still largely 
speculative. A trophic role for MIF has been suggested, given its upregulation in the developmental stage of the 
rat brain [23] and its high basal expression in embryonic hippocampal and neocortical cell cultures [26]. More 
recently, on the basis of its enzymatic properties, MIF has been proposed as a protective factor for 
catecholaminergic neurons [15]. 
In this study, we demonstrated MIF expression in 35 GBMs, both in tumour cells and in hyperplastic endothelial 
cells, confirming and extending the observations of Markert et al. [14]. MIF expression has also been shown in 
other human tumours: melanoma cells [22], pituitary adenomas [25], breast cancer [4], non-small cell lung 
carcinoma and prostate adenocarcinoma [17]. Both in vitro [22] and in vivo [6], MIF promotes angiogenesis. 
Because VEGF is the most potent pro-angiogenic factor currently described in GBMs [13], we searched for a 
possible correlation between MIF and VEGF expression. This study indeed showed a strong correlation between 
MIF and VEGF, suggesting common triggering events or regulatory pathways. Inactivation of p53, a common 
event in the progression of gliomas [11], might be an underlying mechanism, as it has been shown to increase 
VEGF expression [10]. Interestingly, MIF has been reported to overcome p53-mediated cell growth arrest by 
inhibition of p53-dependent transcriptional activity [9]. In this study, we found no correlation between MIF 
expression and p53 immunoreactivity in GBMs, which is an indicator of p53 dysfunction in tumours. However, 
additional studies should look more carefully for a possible association, as our study included only a relatively 
small number of cases and did not explore p53 genetic defects. MIF could also interfere with VEGF expression 
through its ability to override the glucocorticosteroid inhibition of interleukin 1β (IL-1β) and IL-6, both of which 
promote VEGF expression in vitro [7,12,16]. Although the promoting effect of hypoxia on VEGF expression is 
still incompletely understood [8,21], we looked for a possible association between necrotic areas and MIF and/or 
VEGF immunostaining in the tumours. However, immunopositive cells, when present, were found throughout 
the tumour, with no restriction to perinecrotic areas. Finally, other tumour growth-promoting properties of MIF 
could also be of importance in GBMs, as MIF might also inhibit NK [2] and CTL [1] responses against tumour 
antigens. 
In this study, peritumoral reactive astrocytes consistently showed a strong MIF labelling. High MIF expression 
by glial cells has been already reported in nontumoral conditions such as following experimental 
intracerebroventricular LPS administration [3] or in mice infected with Japanese encephalitis virus [24]. In 
humans, raised MIF levels were found in the cerebrospinal fluid (CSF) of patients with multiple sclerosis and 
neuro-Behcet's disease [18]. This is in keeping with the demonstration that physiologically, both at a systemic 
and a local level, MIF acts as a critical component of inflammatory and immune responses by counteracting the 
glucocorticoid inhibition on the acute inflammatory response [16]. In the setting of GBMs, peritumoral reactive 
astrocytes might represent an additional source of MIF, promoting tumour growth and resistance to 
glucocorticoids. 
Finally, in this study, we observed no correlation between the levels of mRNA and the intensity of 
immunostaining for MIF. High density of MIF positive cells was found in tumours with low mRNA expression, 
suggesting a possible storage of MIF in tumour and/or endothelial cells. Accordingly, MIF has been shown to be 
stored in the secretory granules of ACTH-producing cells in the anterior pituitary [5]. In animal models, 
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activation of the hypothalamo-pituitary axis results in the rapid secretion of MIF from the pituitary gland into the 
plasma, followed by a slower time-dependent increase in the expression from pituitary MIF mRNA [5,16]. In 
addition, it has been reported that MIF secretion could be induced by glucocorticoids in hippocampal and 
neocortical rat cell cultures [26]. Therefore, the discrepancy between our results using RT-PCR and 
immunochemistry for MIF might reflect the effects of both cell storage and concurrent corticotherapy. 
In conclusion, we showed in this study that MIF is consistently expressed in human glioblastomas to a level 
similar to or higher than that in the normal brain. We also observed a strong correlation between MIF and VEGF 
expression. MIF combines the properties of a tumour growth promoter and those of a potent counterregulator of 
glucocorticosteroids. Anti-MIF strategies on in vivo and in vitro models could help to determine the role of MIF 
as a new target in the treatment of GBMs. It would also be interesting to determine the status of MIF expression 
in lower grade gliomas and see how it correlates with the extent of microangiogenesis and/or histological 
phenotype. 
Acknowledgements 
We thank the neurosurgeons of the Centre Hospitalier Universitaire de Liège (Professor A. Stevenaert) and of 
the Hôpital de la Citadelle de Liège (Professor J. Born) for their contribution to the collection of cases and O. 
Hougrand for his technical assistance. This work was partly supported by research grants (FIRS) of the Centre 
Hospitalier Universitaire de Liège. Dr C. Munaut is a research associate from the Fond National de la Recherche 
Scientifique (FNRS). 
References 
1   Abe R, Peng T, Sailors J, Bucala R, Metz C. Regulation of the CTL responses by macrophage migration inhibitory factor. J Immunol 
2001; 166: 747-53 
2   Apte R, Sinha D, Mayhew E, Wistow G, Niederkorn J. Role of macrophage migration inhibitory factor in inhibiting NK cell activity and 
preserving immune privilege, J Immunol 1998; 160: 5693-6 
3   Bacher M, Meinhardt A, Lan HY, Dhabhar FS, Mu W, Metz CN, Chesney JA, Gemsa D, Donnelly T, Atkins RC, Bucala R. MIF 
expression in the rat brain: implications for neuronal function. Mol Med 1998 ; 4: 217-30 
4   Bando H, Matsumoro G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M. Expression of macrophage migration 
inhibitory factor in human breast cancer: association with modal spread. Jpn J Cancer Res 2002; 93: 389-96 
5   Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R. MIF is a pituitary-derived 
cytokine that potentiates lethal endotoxaemia. Nature 1993; 365: 756-9 
6   Chesney JA, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in 
angiogenesis and the growth of a murine lymphoma. Mol Med 1999; 5: 181-91 
7   Cohen T, Nahari D, Cerem L, Neufeld G, Levi B. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 
1996 ; 271: 736-41 
8   Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth 
factor transcription in brain tumors in vivo. Cancer Res 2001; 61: 6020-4 
9   Hudson J, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor 
activity. J Exp Med 1999; 190: 1375-82 
10  Kieser A, Weich H, Brandner G, Marmé D, Kölch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth 
factor expression. Oncogene 1994; 9: 963-9 
11  Kleihues P, Cavanee W. Astrocytic tumours. In Tumours of the Nervous System. Eds P Kleihues, W Cavanee. Lyon: IARC Press, 2000; 
9-54 
12  Li J, Perrella M, Tsai J, Yet SF, Hsich CM, Yoshizumi M, Patter C, Endege WO, Zhou F, Lee ME. Induction of vascular endothelial 
growth factor gene expression by interleukin-1b in rat aortic smooth muscle cells, J Biol Chem 1995; 270: 308-12 
13  Machein M, Plate K. VEGF in brain tumors, J NeuroOncol 2000; 50: 109-20 
14  Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapstone TB, Benos DJ et al. Differential 
gene expression profiling in human brain tumors. Physiol Genomics 2001; 5: 21-33 
15  Matsunaga J, Sinha D, Pannell L, Santis C, Solano F, Wistow GJ, Hearing VJ. Enzyme activity of macrophage migration inhibitory 
factor toward oxidized catechola-mines. J Biol Chem 1999; 274: 3268-71 
16  Metz CN, Bucala R. Role of macrophage migration inhibitory factor in the regulation of the immune response. Adv Immunol 1997; 66: 19 
7-223 
17  Meyer-Siegler K, Hudson P. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. 
Urology 1996; 48: 448-52 
18  Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with 
conventional and opticspinal forms of multiple sclerosis and neuro-Bchçet's disease. J Neurol Sci 2000; 179: 127-31 
19  Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R. Localization of macrophage migration inhibitory factor (MIF) to 
secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1995; 1: 781-8 
Published in: Neuropathology & Applied Neurobiology (2002), vol. 28, iss. 6, pp. 452-460. 
Status : Postprint (Author’s version) 
 
20  Ogata A, Nishihira J, Suzuki T, Nagashima K, Tashiro K. Identification of macrophage migration inhibitory factor mRNA expression in 
neural cells of the rat brain by in situ hybridization. Neurosci Lett 1998; 246: 173-7 
21  Parliament M, Allalunis-Turner M, Franko A, Olive PL, Mandyam R, Santos C, Wolokoff B. Vascular endothelial growth factor 
expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br J Cancer 2000; 82: 635-41 
22   Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. High expression of macrophage migration inhibitory factor in 
human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999; 264: 751-8 
23   Suzuki T, Ogata A, Tashiro K, Nagashima K, Tamura M, Nishihira J. Augmented expression of macrophage migration inhibitory factor 
(MIF) in the telencephalon of the developing rat brain. Brain Res 1999; 816: 457-62 
24  Suzuki T, Ogata A, Tashiro K, Nagashima K, Tamura M, Yasui K, Nishihira J. Japanese encephalitis virus up-regulates expression of 
macrophage migration inhibitory factor (MIF) mRNA in the mouse brain. Biochim Biophys Acta 2000; 1517: 100-6 
25 Tampanaru-Sarmesiu A, Stefaneanu L, Thapar K, Kovacs K, Donnelly T, Metz CN, Bucala R. Immunocytochemical localization of 
macrophage migration inhibitory factor in human hypophysis and pituitary adenomas. Arch Pathol Lab Med 1997; 121: 404-10 
26 Vedder H, Krieg JC, Gerlach B, Gemsa D, Bacher M. Expression and glucocorticoid regulation of macrophage migration inhibitory factor 
(MIF) in hippocampal and neocortical rat brain cells in culture. Brain Res 2000; 869: 25-30 
